Menu Search
Equities

Cytokinetics Inc

KK3A:BER

Cytokinetics Inc

Actions
  • Price (EUR)49.60
  • Today's Change-0.20 / -0.40%
  • Shares traded--
  • 1 Year change+65.33%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cytokinetics Inc's revenues fell -92.04% from 94.59m to 7.53m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 388.96m to a larger loss of 526.24m.
Gross margin--
Net profit margin-17,398.82%
Operating margin-16,148.37%
Return on assets-47.34%
Return on equity--
Return on investment-51.07%
More ▼

Cash flow in USDView more

In 2023, Cytokinetics Inc increased its cash reserves by 68.79%, or 46.22m. Cash Flow from Investing totalled 239.25m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 414.33m for operations while cash generated from financing totalled 221.32m.
Cash flow per share-5.24
Price/Cash flow per share--
Book value per share0.9236
Tangible book value per share0.9236
More ▼

Balance sheet in USDView more

Cytokinetics Inc has a Debt to Total Capital ratio of 85.78%.
Current ratio10.39
Quick ratio--
Total debt/total equity6.03
Total debt/total capital0.8578
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.